Vanguard Group Inc Candel Therapeutics, Inc. Put Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CADL
# of Institutions
22Shares Held
3.86MCall Options Held
0Put Options Held
0-
Northpond Ventures, LLC1.94MShares$12 Million8.58% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA812KShares$5.03 Million0.41% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$903,3770.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX82.6KShares$512,0890.0% of portfolio
-
Baystate Wealth Management LLC76.9KShares$476,8420.01% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $179M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...